BioSpace News Archive

OriCiro Genomics, a pioneer in cell-free synthesis and amplification of genome-scale large DNA for advanced therapy and synthetic biology, today announced that it has raised ¥800 million in Series B financing led by The University of Tokyo Edge Capital Partners (UTEC) with participation of ITOCHU Technology Ventures (ITV).

Dr. Tyler Jones is a graduate of Brigham Young University in Provo, UT, and graduated medical school at Ross University School of Medicine.

Parasoft, a global leader in automated software testing for over 30 years, partnered with medical industry leaders, Smiths Medical and Inovytec, to help streamline the delivery of life-saving medical devices using its unified, fully integrated testing solution for C/C++ software development.

Takeda Pharmaceutical Company Limited (TSE: 4502/NYSE:TAK) (“Takeda”) today announced the results of a phase 3 trial investigating the efficacy and safety of recombinant von Willebrand factor (rVWF) prophylaxis,1 one of the 12 abstracts being presented at the International Society on Thrombosis and Haemostasis (ISTH) Virtual Congress 2021.

Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) today announced that it has formed a subsidiary company based in Mexico City, Sorrento Therapeutics Mexico (“Sorrento Mexico”), to support the clinical development and registration of multiple COVID-19 related products Sorrento plans to develop and commercialize in Mexico and other Latin America territories.

Safety and tolerability data for Cohort 2 of the Discover Study reviewed by Data Safety Monitoring Board, allowing the study to proceed with the final cohort

Nextleaf Solutions Ltd. (CSE: OILS) (OTCQB: OILFF) (“Nextleaf”, “OILS”, or the “Company”), is pleased to announce that it has signed a supply agreement with the British Columbia Liquor Distribution Branch (“BCLDB”) for the sale and distribution of Nextleaf’s cannabis oils and branded products under its award-winning prohibition-era brand, Glacial GoldTM.

Universal PropTech Inc. (TSXV: UPI) (OTCQB: UPIPF) (FSE: 8LH) (“UPI” or the “Company”) is pleased to unveil its vision for developing energy assets, “Unleashing The Value From Energy”, in its quest to develop alternate asset class platform.

Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical company with a robust pipeline of novel investigational therapeutics built on protein dysregulation expertise, today announced that it will present preclinical data on two of its Alzheimer’s disease (AD) programs at the Alzheimer’s Association International Conference® 2021 (AAIC®),

Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announces an update on clinical activities.